Cargando…

Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer

PURPOSE: We present here a Zr-89-labeled inhibitor of prostate-specific membrane antigen (PSMA) as a complement to the already established F-18- or Ga-68-ligands. PROCEDURES: The precursor PSMA-DFO (ABX) was used for Zr-89-labeling. This is not an antibody, but a peptide analogue of the precursor fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vázquez, Sergio Muñoz, Endepols, Heike, Fischer, Thomas, Tawadros, Samir-Ghali, Hohberg, Melanie, Zimmermanns, Beate, Dietlein, Felix, Neumaier, Bernd, Drzezga, Alexander, Dietlein, Markus, Schomäcker, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760230/ https://www.ncbi.nlm.nih.gov/pubmed/34370181 http://dx.doi.org/10.1007/s11307-021-01632-x

Ejemplares similares

[(18)F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer
por: Dietlein, Felix, et al.
Publicado: (2020)

Biodistribution and radiation dosimetry of [(18)F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer
por: Hohberg, Melanie, et al.
Publicado: (2019)

Characterization of SnO(2)-based (68)Ge/(68)Ga generators and (68)Ga-DOTATATE preparations: radionuclide purity, radiochemical yield and long-term constancy
por: Sudbrock, Ferdinand, et al.
Publicado: (2014)

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015)

Uptake in non-affected bone tissue does not differ between [(18)F]-DCFPyL and [(68)Ga]-HBED-CC PSMA PET/CT
por: Hammes, Jochen, et al.
Publicado: (2018)

Threshold for defining PSMA-positivity prior to (177)Lu-PSMA therapy: a comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]F-DCFPyL in metastatic prostate cancer
por: Heilinger, Jan, et al.
Publicado: (2023)

Comparative in vivo biodistribution of cells labelled with [(89)Zr]Zr-(oxinate)(4) or [(89)Zr]Zr-DFO-NCS using PET
por: Friberger, Ida, et al.
Publicado: (2023)

The Functional Networks of Prepulse Inhibition: Neuronal Connectivity Analysis Based on FDG-PET in Awake and Unrestrained Rats
por: Rohleder, Cathrin, et al.
Publicado: (2016)

Evaluation of 3-l- and 3-d-[(18)F]Fluorophenylalanines as PET Tracers for Tumor Imaging
por: Krämer, Felicia, et al.
Publicado: (2021)

Current Perspectives on (89)Zr-PET Imaging
por: Yoon, Joon-Kee, et al.
Publicado: (2020)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Novel (89)Zr cell labeling approach for PET-based cell trafficking studies
por: Bansal, Aditya, et al.
Publicado: (2015)

PET Imaging of Acidic Tumor Environment With (89)Zr-labeled pHLIP Probes
por: Bauer, David, et al.
Publicado: (2022)

Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
por: Rosar, Florian, et al.
Publicado: (2023)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

Evaluation of the EPR Effect in the CAM-Model by Molecular Imaging with MRI and PET Using (89)Zr-Labeled HSA
por: Hilbrig, Colmar, et al.
Publicado: (2023)

Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases
por: Hammes, Jochen, et al.
Publicado: (2018)

Assessment of the In Vivo Relationship Between Cerebral Hypometabolism, Tau Deposition, TSPO Expression, and Synaptic Density in a Tauopathy Mouse Model: a Multi-tracer PET Study
por: Endepols, Heike, et al.
Publicado: (2022)

Pet imaging of cytotoxic human T cells using an 89Zr-labeled anti-CD8 minibody
por: Olafsen, Tove, et al.
Publicado: (2015)

(89)Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe
por: Fung, Kimberly, et al.
Publicado: (2020)

In Vivo PET Imaging of Monocytes Labeled with [(89)Zr]Zr-PLGA-NH(2) Nanoparticles in Tumor and Staphylococcus aureus Infection Models
por: Krekorian, Massis, et al.
Publicado: (2021)

Noninvasive Imaging of PSMA in Prostate Tumors with (89)Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives
por: Viola-Villegas, Nerissa Therese, et al.
Publicado: (2014)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

Histologically Confirmed Testicular Metastasis Revealed by [(89)Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Negative Conventional PSMA PET/CT Imaging
por: Rosar, Florian, et al.
Publicado: (2023)

Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2021)

Feasibility of real-time in vivo (89)Zr-DFO-labeled CAR T-cell trafficking using PET imaging
por: Lee, Suk Hyun, et al.
Publicado: (2020)

[(89)Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates
por: Rosar, Florian, et al.
Publicado: (2022)

(89)Zr-cetuximab PET imaging in patients with advanced colorectal cancer
por: Menke-van der Houven van Oordt, Catharina Willemien, et al.
Publicado: (2015)

(89)Zr-Onartuzumab PET imaging of c-MET receptor dynamics
por: Pool, Martin, et al.
Publicado: (2017)

Correction: Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2022)

Detection limit of (89)Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI
por: Lechermann, Laura M., et al.
Publicado: (2020)

PET Imaging of Small Extracellular Vesicles via [(89)Zr]Zr(oxinate)(4) Direct Radiolabeling
por: Khan, Azalea A., et al.
Publicado: (2022)

(89)Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations
por: Kahts, Maryke, et al.
Publicado: (2023)

Synthesis of a novel (89)Zr-labeled HER2 affibody and its application study in tumor PET imaging
por: Xu, Yuping, et al.
Publicado: (2020)

Biodistribution of (89)Zr-DFO-labeled avian pathogenic Escherichia coli outer membrane vesicles by PET imaging in chickens
por: Li, Zhe, et al.
Publicado: (2022)

Preclinical PET and MR Evaluation of (89)Zr- and (68)Ga-Labeled Nanodiamonds in Mice over Different Time Scales
por: Winter, Gordon, et al.
Publicado: (2022)

7-[(18)F]Fluoro-8-azaisatoic Anhydrides: Versatile Prosthetic Groups for the Preparation of PET Tracers
por: Gröner, Benedikt, et al.
Publicado: (2023)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

Development of (89)Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications
por: Lange, Sara E.S., et al.
Publicado: (2016)

A kit formulation for the preparation of [(89)Zr]Zr(oxinate)(4) for PET cell tracking: White blood cell labelling and comparison with [(111)In]In(oxinate)(3)
por: Man, Francis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a0g9i32himpg8mufeq670flfdb